| アブストラクト | OBJECTIVES: Clobazam is a well-known benzodiazepine used as an anti-anxiety drug as well as an anti-epileptic, particularly for patients who are not responding to first-line treatments. Recent case reports have indicated the association of clobazam with drug reaction with eosinophilia systemic symptoms syndrome (DRESS Syndrome). However, DRESS syndrome is not known to be associated with clobazam. Thus, the main objective of the current study was to identify the potential signal of clobazam-associated DRESS Syndrome. MATERIALS & METHODS: US FDA Adverse event reporting system (US FAERS), pharmacovigilance data 2004Q1-2021Q3 was extracted using OpenVigil 2.1-MedDRA-v24. The Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR) with a Chi-Square value (95% confidence interval), and number of cases (>/=3) were used as disproportionality analysis parameters. RESULTS: A total of 141 drug-event combinations were reported and results of disproportionality analysis indicate the positive signal of DRESS syndrome with clobazam. The signal strength was decreased after removing the cases of concomitantly administered drugs (phenytoin, levetiracetam, and valproic acid); however, the association of clobazam with DRESS syndrome remains statistically significant. The subgroup analysis results have shown a greater number of cases in the age group (18-64 years) as compared to other age groups whereas the number of cases in the male and female groups is almost similar. CONCLUSION: The DRESS syndrome is identified as a novel signal with clobazam. However, further causality assessment is required. |
|---|
| ジャーナル名 | Acta neurologica Scandinavica |
|---|
| 投稿日 | 2022/8/28 |
|---|
| 投稿者 | Sharma, Akash; Kumar, Anoop |
|---|
| 組織名 | Department of Clinical Research, Delhi Pharmaceutical Sciences and Research;University (DPSRU), New Delhi, India.;Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University;(DPSRU), New Delhi, India. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36029138/ |
|---|
